Treatment with anti-pcsk9 antibodies

Treatment with anti-pcsk9 antibodies

  • CN 104,093,423 A
  • Filed: 07/10/2012
  • Published: 10/08/2014
  • Est. Priority Date: 07/14/2011
  • Status: Active Application
First Claim
Patent Images

1. proprotein convertases subtilisin kexin9 type (PCSK9) antagonist antibody, be used for the treatment of the disease that is characterised in that low-density lipoprotein cholesterol (LDL-C) level raising in blood, wherein said PCSK9 antagonist antibody with initial application dosage at least about 3mg/kg, approximately 4mg/kg, approximately 5mg/kg or approximately 6mg/kg use;

  • Use subsequently multiple subsequent dose, described subsequent dose and predose are approximately identical or lower than predose, at least about 4 weeks of wherein said predose and first follow-up and extra subsequent dose each interval.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×